ArticleAACE endocrinology and diabetes
Rebound Hypercalcemia in a 14-Year-Old After Denosumab Therapy for Giant Cell Granuloma of the Mandible.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Giant cell granuloma of the bones is often treated with Denosumab. One side effect of this treatment is rebound hypercalcemia after discontinuation of denosumab. Currently, there are no particular guidelines for treating this rebound hypercalcemia. Methods: We describe a case of a 14-year-old male who presented with symptomatic hypercalcemia following the discontinuation of denosumab. He presented to the emergency department with abdominal pain, nausea, and vomiting and was found to have elevated serum calcium at 16.1 mg/dL (2.95 mmol/L). Result: He was treated with zoledronic acid and calcitonin. Three doses of zoledronic acid were required before his calcium levels normalized. Conclusion: There are currently no guidelines regarding the monitoring and treating hypercalcemia following Denosumab therapy, but IV hydration and zoledronic acid have shown promising results. This case report adds to the limited data that zoledronic acid can be used as a first-line therapy for rebound hypercalcemia following Denosumab use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.